Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 133 Cr.
- Current Price ₹ 120
- High / Low ₹ 127 / 53.8
- Stock P/E 13.7
- Book Value ₹ 49.2
- Dividend Yield 0.00 %
- ROCE 28.9 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 13.35 | 57.38 | 89.63 | |
| 10.78 | 45.49 | 74.68 | |
| Operating Profit | 2.57 | 11.89 | 14.95 |
| OPM % | 19.25% | 20.72% | 16.68% |
| 0.05 | 0.09 | 0.19 | |
| Interest | 0.40 | 1.44 | 0.85 |
| Depreciation | 0.22 | 0.77 | 1.21 |
| Profit before tax | 2.00 | 9.77 | 13.08 |
| Tax % | 25.00% | 30.40% | 26.15% |
| 1.49 | 6.79 | 9.67 | |
| EPS in Rs | 3.72 | 8.31 | 8.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 28% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4.00 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 43.59 |
| 13.48 | 14.10 | 12.32 | |
| 8.47 | 10.48 | 9.63 | |
| Total Liabilities | 27.44 | 39.87 | 76.66 |
| 5.25 | 6.09 | 13.21 | |
| CWIP | 0.00 | 0.00 | 0.20 |
| Investments | 0.00 | 0.00 | 0.00 |
| 22.19 | 33.78 | 63.25 | |
| Total Assets | 27.44 | 39.87 | 76.66 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -11.51 | 5.75 | -14.62 | |
| -5.48 | -1.61 | -8.53 | |
| 17.08 | -4.18 | 27.12 | |
| Net Cash Flow | 0.09 | -0.04 | 3.97 |
| Free Cash Flow | -16.99 | 4.14 | -23.15 |
| CFO/OP | -479% | 64% | -75% |
Ratios
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 158.58 | 74.17 | 91.22 |
| Inventory Days | 564.06 | 188.49 | 158.92 |
| Days Payable | 256.32 | 69.41 | 32.32 |
| Cash Conversion Cycle | 466.31 | 193.25 | 217.82 |
| Working Capital Days | 189.47 | 65.33 | 145.63 |
| ROCE % | 46.36% | 28.89% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Capsule Installed Capacity Million Units |
|
|||
| Capsules Capacity Utilization % |
||||
| Capsules Utilized Capacity Crore Units |
||||
| Oral Liquid Capacity Utilization % |
||||
| Oral Liquid Installed Capacity Million Bottles |
||||
| Oral Liquids Utilized Capacity Crore Units |
||||
| Tablet Installed Capacity Million Units |
||||
| Tablets Capacity Utilization % |
||||
| Tablets Utilized Capacity Crore Units |
||||
| Working Capital Days Days |
||||
| Domestic Presence (Indian States) Number |
||||
Extracted by Screener AI
Documents
Announcements
-
Investor Presentation
15 May 2026 - FY26 investor presentation shared; available on Accretion Pharmaceuticals website.
-
Press Release
15 May 2026 - Accretion Pharmaceuticals reported FY26 revenue of ₹89.63 crore and PAT of ₹9.67 crore, up 56.21% and 42.30%.
-
Change in Auditors
8 May 2026 - Board approved FY26 audited results, appointed HR Manager and auditors, and reported IPO proceeds utilization.
-
Appointment
8 May 2026 - Board approved FY26 audited results and appointed HR, internal, and secretarial auditors.
-
Outcome of Board Meeting
8 May 2026 - On 8 May 2026, board approved FY26 audited results and appointed HR manager and auditors.
Concalls
-
Nov 2025Transcript PPT REC
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.